Real-World data sheds light on ribociclib use in early breast cancer

NCT ID NCT07710716

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and what side effects occur. The goal is to understand real-world treatment patterns and safety, not to test if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ribociclib
What this could lead to
If successful, this study could provide valuable insights into how ribociclib is used in everyday clinical practice, helping doctors optimize treatment for early breast cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care across countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis

    Basel, 4056, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.